Identifying advanced NSCLC patients with PD-L1 TPS ≥ 50% who benefit most from monotherapy is crucial, as they are also eligible for combination therapies, including chemotherapy, anti-VEGF agents, and dual ICI regimens, which may increase the risk of toxicity [31,32]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.